Q1 2026 revenue rose 29% year-over-year to DKK 3.3 million, led by strong recurring revenue in Pharma and a major hardware sale to a hospital. Guidance for 2026 remains unchanged, with liquidity expected to last through 2027.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.